Literature DB >> 15606726

In vivo and in vitro evidence for a hepatic modulation of the leptin signal in rats.

G Brabant1, H Nave, R Horn, C Anderwald, G Müller, M Roden.   

Abstract

BACKGROUND: Leptin is primarily secreted by the adipose tissue. It binds not only to hypothalamic structures involved in energy regulation but also to many peripheral tissues including the liver. Leptin circulates in free and receptor-bound forms. Both components are differentially regulated under various pathophysiological conditions and serve different physiological functions. They are released from adipose tissue but previous data suggest an additional formation outside the fat compartment. Here we tested the contribution of the liver in binding and modulating leptin in the circulation.
MATERIALS AND METHODS: In vivo experiments were performed with radioactive labelled leptin with and without pretreatment with unlabelled leptin in freely moving, chronic intravenously cannulated male rats. Livers were investigated by immunohistochemistry and in situ hybridization and immunoblotting was performed, followed by ex vivo liver perfusion studies with human recombinant leptin.
RESULTS: In in vivo experiments radioactively labelled leptin (at low concentrations) is avidly bound to rat liver (greater than 80% of basal serum values 90 min following i.v. infusion). Pre-treatment with excess of unlabelled leptin in vivo revealed a rapid hepatic down-regulation of leptin receptor isoforms when tested by in situ hybridization, immunoblotting or immunohistochemistry. Ex vivo perfusion of rat liver with human recombinant leptin induced a dose- and time-dependent formation of receptor-bound leptin in the perfusate.
CONCLUSIONS: The present data support an active role of the liver in the modulation of the leptin signal through different regulation of the soluble leptin receptor, the bound and free forms of the hormone, which may have important implications for leptin's central efficacy and the development of 'leptin resistance'.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15606726     DOI: 10.1111/j.1365-2362.2004.01427.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Hepatic glucose production and insulin resistance.

Authors:  Michael Roden
Journal:  Wien Med Wochenschr       Date:  2008

2.  Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice.

Authors:  C Owen; E K Lees; L Grant; D J Zimmer; N Mody; K K Bence; M Delibegović
Journal:  Diabetologia       Date:  2013-07-06       Impact factor: 10.122

3.  Hepatic PTP1B Deficiency: The Promise of a Treatment for Metabolic Syndrome?

Authors:  Kendra K Bence
Journal:  J Clin Metab Diabetes       Date:  2010-05

4.  Portal 5-hydroxytryptophan infusion enhances glucose disposal in conscious dogs.

Authors:  Mary Courtney Moore; Kazuhiro Kimura; Haruki Shibata; Tsutomu Honjoh; Masayuki Saito; Carrie A Everett; Marta S Smith; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-03-08       Impact factor: 4.310

5.  Ghrelin and adipokines as circulating markers of disease activity in patients with Takayasu arteritis.

Authors:  Hatice Yilmaz; Vedat Gerdan; Didem Kozaci; Dilek Solmaz; Servet Akar; Gercek Can; Aytac Gulcu; Yigit Goktay; Ismail Sari; Merih Birlik; Nurullah Akkoc; Fatos Onen
Journal:  Arthritis Res Ther       Date:  2012-12-21       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.